HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Published online before print August 20, 2007

This Article Full Text (Reprint (PDF)) All Versions of this Article: jlb.0507273v1 82/5/1353    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rani, M. R. S. Articles by Ransohoff, R. M. Search for Related Content PubMed PubMed Citation Articles by Rani, M. R. S. Articles by Ransohoff, R. M.

© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.0507273

Received for publication May 3, 2007.
Revised June 26, 2007.
Accepted for publication July 30, 2007.

Article

Novel interferon--induced gene expression in peripheral blood cells

M. R. Sandhya Rani ^*, Jennifer Shrock ^*, Swathi Appachi ^*, Richard A. Rudick ^*, Bryan R. G. Williams , and Richard M. Ransohoff ^*@

*Neuroinflammation Research Center, Department of Neurosciences, Lerner Research Institute, and Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, USA; and Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia

^@ To whom correspondence should be addressed. E-mail: ransohr{at}ccf.org.

	Abstract

Type I IFNs are used for treating viral, neoplastic, and inflammatory disorders. The protein products encoded by IFN-stimulated genes (ISGs) likely mediate clinical effects of IFN in patients. Macroarray assays, used for studying ISG induction in IFN-treated patients, comprise genes identified predominantly through analysis of long-term cell lines. To discover genes induced selectively by IFN- in PBMC, we exposed whole blood to physiological concentrations of IFN-. PBMC were prepared, and RNA was extracted, reverse-transcribed, and hybridized to cDNA microarrays, and microarray analysis identified 39 ISGs and 20 IFN-repressed genes (IRGs). Thirty-three ISGs were known previously, and six ISGs were novel. New ISGs included GTP cyclohydrolase 1; hypothetical protein LOC129607; hypothetical protein FLJ38348; leucine aminopeptidase 3; squalene epoxidase; and GTP-binding protein overexpressed in skeletal muscle. Twenty IRGs included IL-1 and CXCL8, which had been identified earlier. CXCL1 was a novel IRG identified in the current study. PCR analysis demonstrated the regulation of six novel ISGs and CXCL1 as an IRG in PBMC and astrocytoma cells. Results were validated using RNA obtained ex vivo from blood of patients after injection with IFN-. Identification of new ISGs and IRGs in primary PBMC will enhance macroarray assays for monitoring IFN responsiveness.

Key Words: microarray • IFN-stimulated genes • IFN-repressed genes • multiple sclerosis

This article has been cited by other articles:

				S. A. Samarajiwa, S. Forster, K. Auchettl, and P. J. Hertzog INTERFEROME: the database of interferon regulated genes Nucleic Acids Res., November 7, 2008; (2008) gkn732v1. [Abstract] [Full Text] [PDF]